Opthea has secured up to $170 million in dilutive financing for the phase 3 clinical trials and pre-commercialization activities for OPT-302, under investigation to treat wet age-related macular degeneration, according to a press release.
Carlyle and Abingworth, through their company Launch Therapeutics, will provide $120 million in three installments, with the option to commit another $50 million. If OPT-302 is approved in a major market, Carlyle and Abingworth will receive a milestone payment, six fixed success payments and variable success payments. Opthea still holds full worldwide